Dabigatran etexilate (Pradaxa®) is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Rapid Review
| Commenced | Completed | Outcome |
| 09/05/2014 | 13/06/2014 | Full Pharmacoeconomic Evaluation Not Recommended |